BURZYNSKI RESEARCH INSTITUTE INC

BZYR ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013
Revenue $0 $0 $0 $0 $0
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $1.3M $1.8M $2.7M $4.0M $6.0M
SG&A Expense $179.1K $157.1K $182.8K $307.7K $450.7K
Operating Income $-1.5M $-2.0M $-2.9M $-4.3M $-6.5M
Operating Margin
Interest Expense
Pretax Income $-1.5M $-2.0M $-2.9M $-4.3M $-6.5M
Income Tax Expense $0 $0 $0 $0
Net Income $-1.5M $-2.0M $-2.9M $-4.3M $-6.5M
Net Margin
EPS (Basic) $-0.01 $-0.02 $-0.02 $-0.03 $-0.05
EPS (Diluted) $-0.01 $-0.02 $-0.02 $-0.03 $-0.05
Shares Outstanding (Basic) 131.4M 131.4M 131.4M 131.4M 131.4M
Shares Outstanding (Diluted) 131.4M 131.4M 131.4M 131.4M 131.4M
Dividends Per Share
← Newer Page 2 of 2 Older →